Tag

Obesity

All articles tagged with #obesity

science1 day ago•6 min saved

Natural Hormone FGF21 Rewires the Brain to Fight Obesity

Researchers found that the hormone FGF21 acts in the hindbrain (nucleus of the solitary tract and area postrema) to regulate metabolism and reduce body weight, signaling a shared yet distinct pathway from GLP-1 drugs. The work, published in Cell Reports, suggests a specific brain circuit could be targeted for obesity and MASH therapies, though current FGF21 analogs can cause GI issues and bone loss, prompting hopes for safer, more precise treatments.

via SciTechDaily|

#fgf21 #glp-1 #hindbrain

science1 day ago•8 min saved

Diet–Gut Signals Flip White Fat into Calorie-Burning Beige Fat in Mice

Researchers found that a low-protein diet activates a specific gut‑bacteria community that emits signals causing white fat to become beige, calorie‑burning fat in mice. Four bacterial strains are needed, and the effect relies on a two‑step process: changes in bile acids push fat cells toward burning energy, and the liver releases FGF21 to boost metabolism. The effect disappears if either signal is blocked, showing the microbiome’s diet‑interpreting role. While promising for metabolic disease targets, human applicability remains unproven and the diet used isn’t recommended for people; the work points to pathways for therapies that mimic these microbial signals rather than extreme diets or probiotics alone.

via SciTechDaily|

#beige-adipocytes #fat-browning #gut-microbiome

health1 day ago•4 min saved

Processed Carbs, Not Taste: A New Take on Overeating

An op-ed argues that obesity isn’t driven mainly by how tasty foods are; instead, fast-digesting carbohydrates raise blood sugar quickly, triggering hunger and cravings, with brain-reward circuits (nucleus accumbens) activated after sugar spikes. Palatability influences what we eat, not how much, and targeting ultra-processed foods would be a blunt policy tool. The author urges focusing on processed carbohydrates to improve satiety and reduce cravings, suggesting it’s possible to enjoy foods—potentially even in a low-carb balance—without overeating.

via statnews.com|

#brain-reward #health #obesity

health1 day ago•1 min saved

Genetics may explain why GLP-1 weight-loss drugs don’t work for everyone

GLP-1 weight‑loss medications help many people but not everyone; about 10–15% of users in trials didn’t lose at least 5% of their body weight. A Nature study suggests DNA differences may explain this variability, indicating genetics could influence who responds to GLP‑1 therapies.

via The Boston Globe|

#genetics #glp-1 #health

health2 days ago•4 min saved

Two Gene Variants Linked to Different Weight-Loss Responses on Obesity Drugs

A Nature study of about 15,000 people using obesity drugs (Wegovy and Mounjaro) finds that certain genetic variants influence weight loss. One variant, especially in two copies, is associated with more weight loss; another variant may raise the risk of nausea. On average, participants lost 11.7% of body weight over eight months, with some achieving as much as 30%. Differences by sex, age, and ancestry, plus drug type, dose, duration and lifestyle, also shape outcomes. While promising for tailoring treatment, these findings are early and not yet practice-changing; further trials are needed to guide precision medicine in obesity care.

via BBC|

#genetics #health #obesity

science2 days ago•42 min saved

Genetic variants forecast GLP-1 weight‑loss response and nausea risk

A large GWAS in 23andMe participants identifies a GLP1R missense variant (rs10305420) linked to greater weight loss from GLP‑1 receptor agonists (~0.76 kg per allele) and links GLP1R and GIPR variants to treatment‑related nausea/vomiting, with a tirzepatide‑specific GIPR signal; replication in All of Us EHR data and integrated predictive models show that combining genetic and non‑genetic factors can stratify patients by efficacy and side‑effect risk, advancing precision obesity treatment.

via Nature|

#gipr #glp1r #obesity

health3 days ago•5 min saved

Genes help explain why obesity drugs work differently for people

Nature reports a study of nearly 28,000 23andMe users who used obesity drugs, linking a GLP-1 receptor gene variant to greater weight loss (about 0.76 kg per copy, ~1.5 kg for two copies) over a median of 8 months, and other variants to higher risk of side effects like nausea. Overall genetic effects on weight loss are modest, but associations with adverse effects are stronger; findings come from self-reported data and are not yet ready to guide clinical practice.

via Nature|

#23andme #genetics #glp-1

science3 days ago•2 min saved

Genes Partly Predict Response to GLP-1 Weight-Loss Shots

Scientists analyzed data from 27,885 patients taking GLP-1 obesity drugs and found two gut-hormone gene variants may partly explain why weight loss and side-effects vary: rs10305420 is linked to slightly more weight loss, while rs1800437 is linked to nausea with tirzepatide. But the genetic contribution is modest; non-genetic factors like sex, drug type, dose, and duration explain much more of the variability, so genetics are not yet ready to guide routine treatment, though the findings could inform future precision approaches.

via The Guardian|

#genetics #glp1 #obesity

business11 days ago•3 min saved

Novo Nordisk rolls out Wegovy subscription to lock in predictable GLP-1 prices

Novo Nordisk launched a multi-month Wegovy subscription for its injectable doses and the high-dose pill, offering 3-, 6-, and 12-month plans with fixed monthly prices and potential savings up to $1,200/year for the injection and $600/year for the pill, via telehealth partners; the program aims to improve adherence and pre-empt competition from Eli Lilly’s upcoming oral GLP-1, and patients can opt out anytime (not yet on NovoCare DTC).

via CNBC|

#business #glp-1 #novo-nordisk

science17 days ago•8 min saved

SLIT3 Wiring in Brown Fat Boosts Calorie Burning and Heat Production

A Nature Communications study reveals brown fat uses SLIT3 fragments, produced by BMP1, to drive blood vessel and nerve growth essential for thermogenesis. In mice, removing SLIT3 or its receptor PLXNA1 impairs nerve and vascular networks and lowers heat production, while human fat analyses suggest SLIT3 activity may influence obesity and insulin sensitivity, pointing to therapies that increase energy expenditure rather than curb appetite.

via SciTechDaily|

#brown-fat #neurovascular #obesity

health18 days ago•16 min saved

Healthy habits required as GLP-1 weight-loss drugs gain momentum

As GLP-1 pills and injections drive up demand for obesity treatment, experts say these drugs work best when paired with healthy lifestyle changes—diet, exercise and ongoing medical supervision—to sustain results and avoid overreliance on medication.

via AP News|

#glp-1 #health #healthy-habits

$Topical testosterone plus exercise cuts dangerous belly fat in older women recovering from hip fracture$

health18 days ago•6 min saved

Topical testosterone plus exercise cuts dangerous belly fat in older women recovering from hip fracture

A study of 66 women over 65 recovering from hip fractures found that adding a topical testosterone gel to an exercise program reduced visceral fat (while total body fat stayed similar), suggesting a targeted approach to fat distribution could improve recovery and aging health without the muscle loss associated with blanket weight loss strategies. The STEP-HI study was published in Obesity Pillars.

via SciTechDaily|

#aging #health #hip-fracture

health-and-medicine22 days ago•5 min saved

Sweetness Cutback Fails to Curb Cravings or Improve Health, Study Suggests

A six-month randomized trial found that changing how sweet foods are in people's diets did not alter their craving for sweetness or improve health markers like weight, heart disease risk, or diabetes risk. The researchers argue that public health guidance should focus on reducing overall sugar and calorie intake rather than simply cutting sweetness.

via ScienceDaily|

#diet #health-and-medicine #obesity

health22 days ago•2 min saved

FDA approves Wegovy HD, a higher-dose weight-loss option under a national priority program

The FDA cleared Wegovy HD (7.2 mg) for weight loss and long-term maintenance in adults with obesity or overweight plus a weight-related condition, marking the fourth approval under the Commissioner’s National Priority Voucher program. The higher dose yielded greater average weight loss with a safety profile consistent with prior semaglutide doses, though GI side effects were common and there is a boxed warning for thyroid C-cell tumors; the approval was granted to Novo Nordisk, and a June public hearing on the voucher program is planned.

via fda.gov|

#fda #health #national-priority-voucher

health22 days ago•14 min saved

FDA clears higher-dose Wegovy injections for obesity treatment

The FDA has approved a higher-dose Wegovy (semaglutide) injectable for obesity treatment, expanding weekly dosing options to help with weight management amid ongoing efforts to address obesity-related health risks.

via AP News|

#fda #health #obesity